Orion Building wellbeing Orion today Orion is developing

Orion Building well-being

Orion today Orion is developing, manufacturing and marketing human and veterinary pharmaceuticals and active pharmaceutical ingredients

Orion today — year 2018 in figures Net sales 977 MEUR Operating profit 253 MEUR Sales by business 7% Personnell ~ 3 200 R&D investments 104 MEUR 50% Sales by market area 5% 4% 15% 34% 6% 32% 31% 16% 6 production sites in Finland Own sales unit in 26 European countries

Orion has operations in 27 countries Finland • • • UK • Sales unit • Research & development Europe • Sales unit in 26 countries India • Support functions ROW • Global partner network for sales HQ Research & development Six production sites Sales unit Support functions

Our businesses Proprietary Products Specialty Products In-house developed drugs and other drugs with valid product protection Generic prescription drugs, OTC and non-medicinal products, biosimilars Animal Health Fermion Medicine and well-being products for animals Active pharmaceutical ingredients (APIs) Contract Manufacturing Production for other pharmaceutical companies

Best-selling pharmaceuticals 1– 9/2019. Indication Net sales (EUR million) Change vs 1− 9/2018 1. Asthma, COPD 75 +16% 2. Parkinson’s disease 70 -7% 3. Acute heart failure 49 +14% 4. Intensive care sedative 46 -5% 5. Biosimilars Rheumatoid arthritis, inflammatory bowel diseases, lymphoma 28 +47% 6. Animal sedatives 28 +20% 7. Inflammatory pain 18 +10% 8. Divina series Menopausal symptoms 14 +5% 9. Anticoagulant 11 -7% 10. Solomet® Inflammation 10 +5% = Products of Proprietary Products business division

Orion’s strategy – Mission to build well-being Growth Sustainability

Orion had ~70, 000 shareholders on 30 June 2019 By number of shares 5% By number of votes Households (Finnish retail) 5% 9% Non-Finnish holders and nominee-registered 8% 3% 6% Private corporations 7% 42% 13% Public sector Non-profit institutions 32% Financial and insurance corporations Other 62% 7%

Research and development Building future well-being

Non-cyclical industry with long time span Global pharma market in 2018: 1. 204, 8 USD billion 1) Time to develop a new drug: 10 to 15 years Cost to develop a drug (including the failures): capitalized cost USD ~2. 2 billion 2) R&D employment in EU: 115. 000+ industry staff members 3) Sources: 1) IQVIA, 2019 Deloitte USD; 2) Deloitte, 2018; 3) EFPIA; 2017

Focus areas of Orion’s R&D Proprietary Products ● Central nervous system ● Oncology ● Respiratory (Easyhaler® product family) Animal Health ● Orion utilises the R&D of proprietary products to develop new medicines for animals Fermion ● APIs to Orion’s proprietary products ● Generic APIs ● Contract development for pharmaceutical companies

Together we can achieve more in R&D Research Early development Target identification and validation Hit to Lead generation Lead optimisation 8‒ 24 mo. 12‒ 24 mo. 18‒ 36 mo. Collaboration with partners Candidate selection, preclinical development 12‒ 24 mo. Late stage development Phase III 12‒ 14 mo. 12‒ 36 mo. 18‒ 48 mo. Collaboration with partners

Orion's key clinical drug development projects Project Indication Easyhaler® tiotropium COPD Darolutamide 1) Prostate cancer (nm. CRPC) I II III Darolutamide 1) Prostate cancer (m. HSPC) I II III ODM-109 (oral levosimendan) ALS I II III ODM-203 (targeted FGFR+VEGFR inhibitor) Solid tumours I II ODM-207 (BET protein inhibitor) Cancer I ODM-208 (CYP 11 A 1 inhibitor) Prostate cancer (CRPC) I ODM-209 (CYP 11 A 1 inhibitor) Prostate cancer (CRPC), breast cancer I 1) In collaboration with Bayer Phase Bioequivalence study = Completed = Ongoing More information on R&D projects: www. orion. fi/en/rd/orion-rd/pipeline/ Registration = Status changed

Proprietary human pharmaceuticals developed by Orion Product Indication Year Sedative for ICU use 2011 Bufomix Easyhaler® 2014 Parkinson’s disease 2003 Formoterol Easyhaler® 2004 Acute decompensated heart failure 2000 Budesonid Easyhaler® 2002 Sedative for ICU use 1999 Beclomet Easyhaler® 1994 1998 Buventol Easyhaler® 1993 Parkinson’s disease Breast cancer 1988 Year Indication Asthma and COPD

Orion in Finland

Orion has large and diversed product portfolio in Finland Orion is part of Finnish Healthcare system Hundreds of different products About every third package sold in Finnish pharmacies is an Orion product

Orion Building well-being